4.6 Article

Between-group differences in infra-patellar fat pad size and signal in symptomatic and radiographic progression of knee osteoarthritis vs non-progressive controls and healthy knees - data from the FNIH Biomarkers Consortium Study and the Osteoarthritis Initiative

Journal

OSTEOARTHRITIS AND CARTILAGE
Volume 25, Issue 7, Pages 1114-1121

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.joca.2017.02.789

Keywords

Infra-patellar fat pad; Knee osteoarthritis; Progression; Knee pain; Healthy; Intermediate-weighted MRI

Funding

  1. Foundation for the NIH (FNIH) Osteoarthritis (OA) Biomarkers Consortium
  2. AbbVie
  3. Amgen Inc.
  4. Arthritis Foundation
  5. Bioiberica SA
  6. DePuy Mitek, Inc.
  7. Flexion Therapeutics, Inc.
  8. GlaxoSmithKline
  9. Merck Serono
  10. Rottapharm j Madaus
  11. Sanofi
  12. Stryker
  13. Pivotal Osteoarthritis Initiative Magnetic Resonance Imaging Analyses (POMA) study (NIH/National Heart, Lung, and Blood Institute) [HHSN2682010000]
  14. NIH [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01AR-2-2261, N01-AR-2-2262]
  15. Merck Research Laboratories
  16. Novartis Pharmaceuticals
  17. Pfizer, Inc.
  18. Paracelsus Medical University Research Fund [PMU-FFF E-14/99/099-RUH]

Ask authors/readers for more resources

Objective: To examine cross-sectional and longitudinal between-group differences of infra-patellar fat pad (IPFP) size and magnetic resonance imaging (MRI) signal from fat-suppressed intermediate-weighted images with clinically relevant symptomatic and radiographic progression of knee osteoarthritis (OA), vs healthy references. Methods: We studied 110 case knees (Kellgren-Lawrence Grade [KLG1-3]) with radiographic (>= 0.7 mm loss in joint space width [JSW]) and symptomatic progression (>= +9/100 units on the Western Ontario and McMasters Universities Osteoarthritis Index [WOMAC] knee pain subscale) vs 118 control knees without progression from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium cohort. We further studied 88 knees from the Osteoarthritis Initiative (OAI) healthy reference cohort without (risk factors) of knee OA. The IPFP was manually segmented using baseline and year-2 sagittal fat-suppressed intermediate-weighted spin-echo 3 T MRIs. Baseline measures and longitudinal change in IPFP volume and 3D MRI signal (mean, standard deviation [SD]) were compared between groups. Results: No statistically significant baseline differences in IPFP volume, 3D MRI signal mean or signal heterogeneity (SD) were observed between progressor and non-progressor OA knees. Yet, the IPFP 3D MRI signal SD, but not its volume, was statistically significantly greater in OA vs healthy knees. No statistically significant 2-year changes in IPFP volume were observed in either group, but the increase in 3D MRI signal heterogeneity (SD) was greater in progressor vs non-progressor knees, and was greater in OA vs healthy knees. Conclusion: Whereas IPFP-related morphometric measures did not statistically significantly differ between groups, a stronger increase in 3D IPFP MRI signal and signal heterogeneity may be associated with radiographic/symptomatic progression of OA, when compared to non-progressive OA or healthy knees. (C) 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available